Drug intelligence / Profile preview

Refresh Optive UD

Development stage
Unknown
Lead developer
Allergan
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Refresh Optive UD (Unit Dose) is a preservative-free, topical ophthalmic solution indicated for the temporary relief of burning, irritation, and discomfort due to dry eye disease or exposure to environmental factors. Developed by Allergan (now part of AbbVie), the formulation features a dual-action approach combining carboxymethylcellulose sodium (0.5%) and glycerin (0.9%). Carboxymethylcellulose acts as a mucomimetic lubricant that stabilizes the tear film and binds to corneal epithelial cells to provide prolonged relief, while glycerin serves as an osmoprotectant that helps protect the ocular surface from hyperosmotic stress. As a unit-dose product, it is packaged in single-use vials to ensure sterility without the need for preservatives, making it suitable for patients with sensitive eyes or those requiring frequent application. In clinical research, it is frequently utilized as a standard-of-care comparator in Phase 3 trials for novel artificial tear formulations, such as ABBV-444.

Brand names
Refresh Optive UDRefresh Optive Unit DoseRefresh Optive Lubricant Eye Drops
Other names
Refresh Optive Preservative-Free

Beyond the preview

Go deeper on Refresh Optive UD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refresh Optive UD.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call